J. Lyons

发表

Two G protein oncogenes in human endocrine tumors.

E. Kawasaki, H. Bourne, G. Harsh, 1990, Science.

Point Mutation of the ms Protooncogenes and Chromosome Aberrations in Acute Nonlymphocytic Leukemia and Preleukemia Related to Therapy with Alkylating Agents1

C. Bartram, J. Pedersen‐Bjergaard, J. Lyons, 2006 .

Cellular oncogenes in human teratocarcinoma cell lines.

H. Tesch, C. Bartram, D. Bronson, 1990, International journal of andrology.

Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein.

H. Bourne, R. Davis, G. Harsh, 1990, The Journal of clinical endocrinology and metabolism.

Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci.

W. Hiddemann, J. Harbott, W. Ludwig, 1989, Leukemia.

Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation.

H. Drexler, M. Buschle, C. Bartram, 1988, Leukemia.

Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents.

C. Bartram, J. Pedersen‐Bjergaard, J. Lyons, 1988, Cancer research.

MINIMAL RESIDUAL LEUKAEMIA IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER T-CELL DEPLETED BONE-MARROW TRANSPLANTATION

C. Bartram, J. Lyons, R. Arnold, 1989, The Lancet.

Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy.

G. Mufti, C. Bartram, J. Lyons, 1988, The New England journal of medicine.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

S. Baylin, D. Matei, K. Nephew, 2018, Clinical Cancer Research.

Identification of mutant forms of G-protein alpha subunits in human neoplasia by polymerase chain reaction-based techniques.

J. Lyons, 1994, Methods in enzymology.

46 – ANALYSIS OF ras GENE POINT MUTATIONS BY PCR AND OLIGONUCLEOTIDE HYBRIDIZATION

J. Lyons, 1990 .

Aristolochic Acid I Induced Tumors in Wistar Rats Contain Activating Mutations in Codon 61 of the H-ras Protooncogene

C. Bartram, M. Wiessler, H. Schmeiser, 1989 .

ras gene mutations and clonal analysis using RFLPs of X-chromosome genes in myelodysplastic syndromes.

C. Bartram, M. Buschle, J. Lyons, 1989, Haematology and blood transfusion.

hematopoietic malignancies -deoxycytidine (decitabine) in ' hypomethylating agent 5-aza-2 Phase 1 study of low-dose prolonged exposure schedules of the

J. Issa, Rajan Mannari, H. Kantarjian, 2013 .

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Jorge Cortes, Guillermo Garcia-Manero, Francis J Giles, 2004, Blood.

Rapid and non‐radioactive prenatal diagnosis of β thalassaemia and sickle cell disease: application of the polymerase chain reaction (PCR)

C. Bartram, A. Kulozik, E. Kohne, 1988, British journal of haematology.

ConvenientScreeningfor Hemoglobin Variantsby Usingthe DiamatHPLCSystem

C. Bartram, E. Kohne, J. Lyons, 1990 .

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

H. Heimpel, G. Mufti, H. Drexler, 1989, Blood.

Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.

G. Mufti, C. Bartram, J. Lyons, 1988, Blood.

Concurrent mutations in two different ras genes in acute myelocytic leukemias.

C. Bartram, J. Lyons, J. Janssen, 1987, Nucleic acids research.

High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas

C. Bartram, K. Grünewald, J. Lyons, 1989, International journal of cancer.

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

C. Bartram, J. Bos, J. Lyons, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Ras mutations in Hodgkin's disease.

H. Tesch, C. Bartram, H. Drexler, 1988, Leukemia.

Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues.

C. Bartram, A. Buchmann, J. Lyons, 1990, Cancer research.

Mutation of the ms Protooncogenes and Chromosome Aberrations in Acute Nonlymphocytic Leukemia and Preleukemia Related to Therapy with Alkylating Agents 1

C. Bartram, J. Pedersen‐Bjergaard, J. Lyons, 2006 .

The polymerase chain reaction and cancer diagnostics

J. Lyons, 1992, Cancer.

Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications

H. Bourne, F. McCormick, O. Clark, 1992, World Journal of Surgery.

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

F. Villarroya, M. Vinciguerra, V. Pazienza, 2016, Epigenetics.

The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

D. Matei, K. Nephew, J. Turchi, 2014, Clinical Cancer Research.

Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.

C. Rosenfeld, J. Lyons, M. Mccullar, 2003, Current opinion in investigational drugs.

Significance of P53 in human thyroid tumors

H. Röher, J. Lyons, P. Goretzki, 1994, World Journal of Surgery.

Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage.

A. Nikitin, M. Rajewsky, J. Lyons, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Incidence of ras gene mutations in neuroblastoma

C. Bartram, J. Lyons, K. Ballas, 1988, European Journal of Pediatrics.

465 SGI-110, a Novel Second Generation DNa Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines

J. Lyons, P. Taverna, M. Azab, 2012 .

Detection of enteroviral ribonucleic acid in myocardial biopsies from patients with idiopathic dilated cardiomyopathy by polymerase chain reaction.

K. Grünewald, A. Schwaiger, V. Mühlberger, 1993, American heart journal.